Posts Tagged ‘Pharmaceuticals’

ASX Company News: Pharmaxis Enters JV Agreement TO Market Bronchitol In Europe

Wednesday, September 1st, 2010

Pharmaceutical company Pharmaxis (PXS) announced it has finalised a strategic marketing and sales service agreement for the commercialisation of Bronchitol for cystic fibrosis in Europe. Ahead of anticipated regulatory approval for Bronchitol, Pharmaxis has signed a six year agreement with the highly respected Quintiles organisation to support the launch and commercialisation of the product in Western Europe.

Pharmaxis Acting Chief Executive Officer Gary Phillips said, “This important development means that Pharmaxis will move into the key European markets with a clear commercialisation plan. We will be bringing on board the European expertise and capabilities of a well recognised team of leaders in the field. “Bronchitol is a new advance in the treatment of cystic fibrosis and it’s vital that we engage fully with the CF communities, healthcare professionals, funding bodies and governments across Europe as efficiently as possible.  We have selected Quintiles to help manage market launch and accelerate product uptake because the local experience of the Quintiles organisation will allow rapid access to each of the individual country markets.”

Quintiles is a global biopharmaceutical services company offering clinical, commercial, consulting and capital solutions. The Quintiles network employs 20,000 people across 60 countries. Once approved, Pharmaxis plans to launch Bronchitol across Western Europe, initially in Germany and the UK in the first quarter of 2011. The Pharmaxis contract sales representatives will be supported and managed by the Quintiles organisation throughout Western Europe while marketing and market support will be managed by the Pharmaxis office in the UK. Quintiles will provide a broad range of commercial support for Bronchitol including development of the overall market access strategy, pricing and reimbursement, local market access, and  recruitment and management of field based sales teams and product managers. Pharmaxis Ltd is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and immune disorders.

www.pharmaxis.com.au

http://www.traderdealer.com.au/Fundamentals/pxs

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

ASX Company News: HalcyGen Pharmaceuticals Enters Asian Distribution Agreement

Friday, August 27th, 2010

HalcyGen Pharmaceuticals Limited (HGN) is pleased to announce that it has signed a distribution agreement with Pan- Malayan Pharmaceuticals Pte Ltd for the distribution of DORYX, ASTRIX and ERYC in Singapore.

HalcyGen’s CEO, Dr Roger Aston said “This distribution agreement will expand our sales in Asia. Pan-alayan is a well respected sales and distribution organization and we are very pleased to have this company work with us.” DORXY and ERYC are oral antibiotics and ASTRIX is low dose aspirin. These products, which incorporate Mayne Pharma’s proprietary drug delivery technology, are  manufactured at the company’s facility in Salisbury, South Australia.

HalcyGen was founded to bridge the gap between main stream pharmaceutical companies and high volume generics companies through the development and licensing of new improved proprietary generic formulations known as “Super Generics” or “High Functionality Generics”. HalcyGen acquired Mayne Pharma International Pty Ltd (MPI) in November 2009. The company has substantial assets and revenues. MPI was formerly known as FH Faulding & Co Ltd, and is a specialist pharmaceutical company with an intellectual property portfolio built around the optimisation and delivery of oral dosage form drugs. MPI has a long and successful history in developing and commercialising improved pharmaceuticals, and has launched and marketed numerous products through partnerships with global licensees. Pan-Malayan Pharmaceuticals Pte Ltd is a Singapore-based full-service company specializing in sales, marketing and distribution of innovative human health care products. Pan-Malayan also has operations in Indonesia, Vietnam, Cambodia and Malaysia where it is known as Hyphens.

www.halcygen.com

http://www.traderdealer.com.au/Fundamentals/hgn

Post to Twitter

Tags: , , ,
Posted in ASX Company News | No Comments

Immuron To Develop Influenza Preventative

Saturday, May 22nd, 2010

Nycomed and Immuron (IMC) intend to collaborate to complete the development of an antibody-based product based on Immuron’s technology and existing pre- clinical program to prevent influenza in humans. The aim is to target this product into the large over-the-counter cold-and-flu market. The influenza specific market is in excess of US$2 billion per year globally, while the pharmacy cold-and-flu segment of the OTC market is $150 million per year retail in Australia alone (according to IMS figures, 2008). Input in this product is expected to come from Immuron in Melbourne, Australia as well as from Jerusalem, Israel. Expertise from Nycomed will be sourced from both Nycomed in Europe and in Australia.

Nycomed is a privately owned pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. Nycomed is one of the top 25 global pharmaceutical companies and 16 in rank world-wide for consumer healthcare products with a total net turnover of more than 3.5 billion Euro (AU$6 billion). Nycomed Australia, based in Sydney, has grown quickly over the last 7 years to achieve over AU$100 million turnover and employs 100 staff locally. Nycomed is most active in the areas of gastroenterology, respiratory diseases, pain management and tissue management. A key corporate strategy within Nycomed is to license in new promising products and to work with innovative partners  to co-develop their concepts to a profitable conclusion.

Immuron is a biopharmaceutical company focused on oral immunotherapy using dairy- derived polyclonal antibody products for humans. Current products target infectious diseases of the gastrointestinal tract, while more recent projects are targeting immunotherapy to influence chronic diseases such as diabetes type 2 and fatty liver (NASH), and to prevent and treat respiratory infection with influenza. Immuron’s main scientific alliances are with Hadassah Medical Centre (Israel) and University of Melbourne (Australia).

www.immuron.com

Post to Twitter

Tags: , , ,
Posted in ASX Company News | No Comments

Stirling Products Acquires Canadian Manufacuring Plant

Thursday, December 3rd, 2009

Australian healthcare company Stirling Products Limited (STI) is pleased to advise that the Company has been notified that it has been successful in negotiating the acquisition of a 4,310 square metre (46,400 square feet) near new fully equipped and licensed pharmaceutical manufacturing facility in Canada. The facility is being sold to Stirling Products through an administrator of a Canadian listed Company that collapsed as a direct consequence of the Global Financial Crisis. The fully licensed pharmaceutical plant comprises a total 4,310 sq m (46,400 sq ft) of fully equipped and fitted facility that was completed during the course of last year. The facility fit-out of plant, equipment and furnishings is first-class and is fully operational.

Stirling Products Managing Director, Peter Boonen stated: “This sale will complete another key strategic milestone in the global positioning of the Company as well as give the Company total control over a number of its unique products. Further, as a freehold property, this facility will also add to and underpin the Company’s growing asset position.”

www.stirlingproducts.net

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

Acrux Signs South Korean Distribution Agreement

Monday, July 13th, 2009

Acrux (ACR) today announced a marketing and distribution agreement for its unique transdermal estradiol spray product Ellavie™ in South Korea. Ellavie™ will be marketed by Dream Pharma Corporation, which is a wholly owned subsidiary of the South Korean diversified conglomerate, Hanwha Group. Under the exclusive distribution agreement, Acrux will receive fees on signing, on confirmation of marketing authorisation and on market launch. In addition, Acrux will receive an ongoing distribution fee based on net sales of Ellavie™. Dream Pharma is responsible for obtaining marketing authorisation in South Korea, utilising the product dossier previously approved by the US Food and Drug Administration (FDA).Ellavie™ is currently marketed in the US as Evamist™ and is under evaluation by the regulatory authorities in Australia and Sweden.

“Dream Pharma Corporation is a successful and rapidly growing pharmaceutical company in South Korea, with the strong backing of its parent company the Hanwha Group” said Acrux CEO Dr Richard Treagus. “We are very pleased to be partnering Ellavie™ in our first Asian market, building on the recently announced deals in Southern Africa and Switzerland. We anticipate entering into further distribution agreements for Ellavie™ in other pharmaceutical markets around the world”.

Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin. Acrux has one product, Evamist™ (brand name Ellavie™ outside the USA) to treat menopause symptoms, marketed by its licensee in the USA. It has licensed US rights for Evamist™ to KV Pharmaceutical and has appointed distributors for Ellavie™ in other markets around the world. It has also licensed its technology to Eli Lilly and Company for veterinary healthcare products and US rights for Testosterone MDTS to VIVUS.

www.acrux.com.au

www.dreampharma.co.kr

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

Acrux To Distribute Product in South Africa

Friday, June 5th, 2009

Acrux ( ACR) today announced the first marketing and distribution agreement outside the US and Australia for its unique estradiol spray, Ellavie™. Distribution rights for the spray have been granted to a leading South African pharmaceutical company, Aspen Pharmacare . Aspen will market and promote the product in South Africa. Under the exclusive distribution agreement, Acrux will receive a signing fee, further fees on achievement of marketing authorisation in South Africa and a distribution fee based on net sales. Aspen is responsible for obtaining the necessary regulatory approvals for the product. Ellavie™ is currently marketed in the US as Evamist™ and is under evaluation by the regulatory authorities in Australia and Sweden.

“We are very pleased to be working with Aspen, given their market position and formidable track record of delivery in the southern African region”, said Acrux CEO Dr Richard Treagus. “We anticipate entering into further agreements for Ellavie™ with distributors in a number of other pharmaceutical markets around the world”.

Aspen is Africa’s largest pharmaceutical manufacturer and is a major supplier of high-quality, affordable pharmaceutical products to both its domestic and export markets. The Group also has a strong manufacturing base including fifteen manufacturing facilities across eleven sites on three continents. ThinkSmart is a leading international financial services company that is focused on the delivery of B2B finance products through the retail environment. Ellavie™ is a small, hand-held spray, designed to provide an easy and convenient means of delivering a preset dose of estradiol via the skin, in order to reduce symptoms that affect quality of life for many menopausal women. Ellavie™ is placed gently against the skin and an actuator button is pushed, releasing a light spray containing a proprietary formulation of estradiol. The spray is fast drying, non-irritating and invisible after application. Estradiol is released into the blood stream on a sustained basis over 24 hours.

www.acrux.com.au

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments